A retrospective study assessing demographical and clinical descriptions of patients at least 65 years of age who were treated with onabotA at the Hartford Healthcare Headache Center over a two- year period, and to evaluate the safety and efficacy of this treatment
Latest Information Update: 04 Aug 2022
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Migraine
- Focus Therapeutic Use
Most Recent Events
- 04 Aug 2022 New trial record
- 12 Jun 2022 Results presented at the 64th Annual Scientific Meeting of the American Headache Society